Business Context and Reporting Period
This Form 8-K is a current report filed by Transdel Pharmaceuticals, Inc. (not Harrow, Inc.) on November 21, 2008. The filing reports the appointment of a new director to the Board of Directors effective November 21, 2008.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial data disclosed relates to the compensation package for the new director:
- Stock Options: 80,000 shares at an exercise price of $0.70 per share (vesting over 5 years) and 25,000 shares at $0.70 per share (vesting over 1 year).
- Restricted Stock: 25,000 shares issued at $0.70 per share (vesting over 1 year).
- Stock Price: The closing bid price on the grant date was $0.70 per share.
Material Changes
The material change reported is the addition of Lynn Swann to the Board of Directors. Mr. Swann brings experience as a former professional athlete, sports broadcaster, and executive in marketing, communications, and finance. He currently serves on the boards of H.J. Heinz Company, Hershey Entertainment and Resorts Company, and Harrah's Entertainment, Inc.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies. It is strictly a disclosure of a corporate governance event and the associated compensatory arrangements.
Key Facts for Investor Verification
- Verify the company name is Transdel Pharmaceuticals, Inc., as the request metadata incorrectly listed "Harrow, Inc."
- Confirm the total equity compensation granted to the new director: 105,000 options and 25,000 restricted shares.
- Note the vesting schedules: 5 years for the primary option grant and 1 year for the secondary option and restricted stock.
- Review the attached press release (Exhibit 99.1) for additional context on the appointment.